BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//TrialSonar//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:TrialSonar · $PFE readouts
X-WR-CALDESC:Clinical-trial primary completion dates from ClinicalTrials.go
 v\, refreshed nightly by TrialSonar. Not investment advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05995964-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20261112
DTEND;VALUE=DATE:20261113
SUMMARY:PF-07275315 readout (P2) · Pfizer $PFE
DESCRIPTION:A Study To Learn About Two Study Medicines (PF-07275315 And PF-
 07264660) In People Who Have Moderate To Severe Atopic Dermatitis\n\nPrima
 ry completion date: 2026-11-12 (estimated)\nOriginally planned: 2026-04-06
  (+7.2 months)\nPhase 2 · Immuno · Atopic Dermatitis\nEnrollment: 507 ·
  Sites: 96\n\nPrimary completion = last participant's primary-endpoint dat
 a collected\; topline results usually follow weeks to months later. Sponso
 r-reported\, often an estimate. Not investment advice.\n\nhttps://trialson
 ar.netlify.app/radar.html?nct=NCT05995964\nhttps://clinicaltrials.gov/stud
 y/NCT05995964
URL:https://trialsonar.netlify.app/radar.html?nct=NCT05995964
CATEGORIES:Immuno,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06641466-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20261129
DTEND;VALUE=DATE:20261130
SUMMARY:Rimegepant readout (P3) · Pfizer $PFE
DESCRIPTION:A Study to Learn About the Study Medicine Called Rimegepant in 
 Women When Used for Intermittent Prevention of Menstrual Migraine\n\nPrima
 ry completion date: 2026-11-29 (estimated)\nOriginally planned: 2026-06-03
  (+5.9 months)\nPhase 3 · Neuro · Menstrual Migraine\nEnrollment: 723 ·
  Sites: 123\n\nPrimary completion = last participant's primary-endpoint da
 ta collected\; topline results usually follow weeks to months later. Spons
 or-reported\, often an estimate. Not investment advice.\n\nhttps://trialso
 nar.netlify.app/radar.html?nct=NCT06641466\nhttps://clinicaltrials.gov/stu
 dy/NCT06641466
URL:https://trialsonar.netlify.app/radar.html?nct=NCT06641466
CATEGORIES:Neuro,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07029711-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20261202
DTEND;VALUE=DATE:20261203
SUMMARY:B7981027 readout (P3) · Pfizer $PFE
DESCRIPTION:A Study to Learn About Medicine Called Ritlecitinib in Children
  Aged Between 6 to 12 Years With Severe Alopecia Areata\n\nPrimary complet
 ion date: 2026-12-02 (estimated)\nOriginally planned: 2027-05-02 (-5.0 mon
 ths)\nPhase 3 · Immuno · Severe Alopecia Areata\nEnrollment: 208 · Site
 s: 84\n\nPrimary completion = last participant's primary-endpoint data col
 lected\; topline results usually follow weeks to months later. Sponsor-rep
 orted\, often an estimate. Not investment advice.\n\nhttps://trialsonar.ne
 tlify.app/radar.html?nct=NCT07029711\nhttps://clinicaltrials.gov/study/NCT
 07029711
URL:https://trialsonar.netlify.app/radar.html?nct=NCT07029711
CATEGORIES:Immuno,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07500506-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20261204
DTEND;VALUE=DATE:20261205
SUMMARY:VLA15 readout (P3) · Pfizer $PFE
DESCRIPTION:A Study to Learn About the Safety\, Tolerability\, and Immunoge
 nicity of a Fifth Dose of 6-Valent OspA-Based Lyme Disease Vaccine\n\nPrim
 ary completion date: 2026-12-04 (estimated)\nPhase 3 · Infectious · Lyme
  Disease\nEnrollment: 1712 · Sites: 22\n\nPrimary completion = last parti
 cipant's primary-endpoint data collected\; topline results usually follow 
 weeks to months later. Sponsor-reported\, often an estimate. Not investmen
 t advice.\n\nhttps://trialsonar.netlify.app/radar.html?nct=NCT07500506\nht
 tps://clinicaltrials.gov/study/NCT07500506
URL:https://trialsonar.netlify.app/radar.html?nct=NCT07500506
CATEGORIES:Infectious,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07228390-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20261208
DTEND;VALUE=DATE:20261209
SUMMARY:Ritlecitinib readout (P2) · Pfizer $PFE
DESCRIPTION:A 16-Week Study to Learn About the Study Medicine Called Ritlec
 itinib in Adults With Long Lasting Painful Red Skin Lumps\, Known by the M
 edical Term\, Hidradenitis Suppurativa\, or H…\n\nPrimary completion dat
 e: 2026-12-08 (estimated)\nOriginally planned: 2027-03-05 (-2.9 months)\nP
 hase 2 · Infectious · Hidradenitis Suppurativa\nEnrollment: 128 · Sites
 : 57\n\nPrimary completion = last participant's primary-endpoint data coll
 ected\; topline results usually follow weeks to months later. Sponsor-repo
 rted\, often an estimate. Not investment advice.\n\nhttps://trialsonar.net
 lify.app/radar.html?nct=NCT07228390\nhttps://clinicaltrials.gov/study/NCT0
 7228390
URL:https://trialsonar.netlify.app/radar.html?nct=NCT07228390
CATEGORIES:Infectious,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04879329-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20261211
DTEND;VALUE=DATE:20261212
SUMMARY:disitamab vedotin readout (P2) · Seagen\, a wholly owned subsidiar
 y of Pfizer $PFE
DESCRIPTION:A Study of Disitamab Vedotin Alone or With Pembrolizumab in Uro
 thelial Cancer That Expresses HER2\n\nPrimary completion date: 2026-12-11 
 (estimated)\nOriginally planned: 2023-01-31 (+46.3 months)\nPhase 2 · Onc
 ology · Urothelial Carcinoma\nEnrollment: 372 · Sites: 221\n\nPrimary co
 mpletion = last participant's primary-endpoint data collected\; topline re
 sults usually follow weeks to months later. Sponsor-reported\, often an es
 timate. Not investment advice.\n\nhttps://trialsonar.netlify.app/radar.htm
 l?nct=NCT04879329\nhttps://clinicaltrials.gov/study/NCT04879329
URL:https://trialsonar.netlify.app/radar.html?nct=NCT04879329
CATEGORIES:Oncology,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07219615-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20261225
DTEND;VALUE=DATE:20261226
SUMMARY:Ritlecitinib 50 mg readout (P2) · Pfizer $PFE
DESCRIPTION:A Study to Learn About Ritlecitinib for the Potential Treatment
  of Chronic Spontaneous Urticaria in Adults.\n\nPrimary completion date: 2
 026-12-25 (estimated)\nPhase 2 · Immuno · Chronic Spontaneous Urticaria\
 nEnrollment: 200 · Sites: 77\n\nPrimary completion = last participant's p
 rimary-endpoint data collected\; topline results usually follow weeks to m
 onths later. Sponsor-reported\, often an estimate. Not investment advice.\
 n\nhttps://trialsonar.netlify.app/radar.html?nct=NCT07219615\nhttps://clin
 icaltrials.gov/study/NCT07219615
URL:https://trialsonar.netlify.app/radar.html?nct=NCT07219615
CATEGORIES:Immuno,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05909397-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:VERITAC-3 readout (P3) · Pfizer $PFE
DESCRIPTION:Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole 
 + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer\n\nPrimary completio
 n date: 2026-12-30 (estimated)\nOriginally planned: 2028-08-28 (-19.9 mont
 hs)\nPhase 3 · Oncology · Breast Cancer\nEnrollment: 59 · Sites: 29\n\n
 Primary completion = last participant's primary-endpoint data collected\; 
 topline results usually follow weeks to months later. Sponsor-reported\, o
 ften an estimate. Not investment advice.\n\nhttps://trialsonar.netlify.app
 /radar.html?nct=NCT05909397\nhttps://clinicaltrials.gov/study/NCT05909397
URL:https://trialsonar.netlify.app/radar.html?nct=NCT05909397
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04553133-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:PF-07104091 monotherapy dose escalation readout (P2) · Pfizer $PFE
DESCRIPTION:PF-07104091 as a Single Agent and in Combination Therapy\n\nPri
 mary completion date: 2026-12-31 (estimated)\nOriginally planned: 2025-04-
 18 (+20.4 months)\nPhase 2 · Oncology · Small Cell Lung Cancer\, Ovarian
  Cancer\, Breast Cancer\nEnrollment: 157 · Sites: 22\n\nPrimary completio
 n = last participant's primary-endpoint data collected\; topline results u
 sually follow weeks to months later. Sponsor-reported\, often an estimate.
  Not investment advice.\n\nhttps://trialsonar.netlify.app/radar.html?nct=N
 CT04553133\nhttps://clinicaltrials.gov/study/NCT04553133
URL:https://trialsonar.netlify.app/radar.html?nct=NCT04553133
CATEGORIES:Oncology,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05059522-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Avelumab readout (P3) · Pfizer $PFE
DESCRIPTION:Continued Access Study for Participants Deriving Benefit in Pfi
 zer-Sponsored Avelumab Parent Studies That Are Closing\n\nPrimary completi
 on date: 2026-12-31 (estimated)\nOriginally planned: 2025-12-31 (+12.0 mon
 ths)\nPhase 3 · Oncology · Advanced Malignancies\, NSCLC\, Ovarian Cance
 r\nEnrollment: 77 · Sites: 71\n\nPrimary completion = last participant's 
 primary-endpoint data collected\; topline results usually follow weeks to 
 months later. Sponsor-reported\, often an estimate. Not investment advice.
 \n\nhttps://trialsonar.netlify.app/radar.html?nct=NCT05059522\nhttps://cli
 nicaltrials.gov/study/NCT05059522
URL:https://trialsonar.netlify.app/radar.html?nct=NCT05059522
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05035212-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270118
DTEND;VALUE=DATE:20270119
SUMMARY:RENOIR readout (P3) · Pfizer $PFE
DESCRIPTION:Study to Evaluate the Efficacy\, Immunogenicity\, and Safety of
  RSVpreF in Adults.\n\nPrimary completion date: 2027-01-18 (estimated)\nOr
 iginally planned: 2024-06-19 (+31.0 months)\nPhase 3 · Respiratory · Low
 er Respiratory Tract Illness\nEnrollment: 38861 · Sites: 263\n\nPrimary c
 ompletion = last participant's primary-endpoint data collected\; topline r
 esults usually follow weeks to months later. Sponsor-reported\, often an e
 stimate. Not investment advice.\n\nhttps://trialsonar.netlify.app/radar.ht
 ml?nct=NCT05035212\nhttps://clinicaltrials.gov/study/NCT05035212
URL:https://trialsonar.netlify.app/radar.html?nct=NCT05035212
CATEGORIES:Respiratory,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07653100-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270125
DTEND;VALUE=DATE:20270126
SUMMARY:RSVpreF readout (P3) · Pfizer $PFE
DESCRIPTION:A Phase 3 Study in India to Describe the Safety and Immunogenic
 ity of RSVpreF\n\nPrimary completion date: 2027-01-25 (estimated)\nPhase 3
  · Infectious · Respiratory Syncytial Virus (RSV)\nEnrollment: 540 · Si
 tes: 13\n\nPrimary completion = last participant's primary-endpoint data c
 ollected\; topline results usually follow weeks to months later. Sponsor-r
 eported\, often an estimate. Not investment advice.\n\nhttps://trialsonar.
 netlify.app/radar.html?nct=NCT07653100\nhttps://clinicaltrials.gov/study/N
 CT07653100
URL:https://trialsonar.netlify.app/radar.html?nct=NCT07653100
CATEGORIES:Infectious,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05911295-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270129
DTEND;VALUE=DATE:20270130
SUMMARY:disitamab vedotin readout (P3) · Seagen\, a wholly owned subsidiar
 y of Pfizer $PFE
DESCRIPTION:Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previou
 sly Untreated Urothelial Cancer Expressing HER2\n\nPrimary completion date
 : 2027-01-29 (estimated)\nOriginally planned: 2026-06-30 (+7.0 months)\nPh
 ase 3 · Oncology · Urothelial Carcinoma\nEnrollment: 412 · Sites: 268\n
 \nPrimary completion = last participant's primary-endpoint data collected\
 ; topline results usually follow weeks to months later. Sponsor-reported\,
  often an estimate. Not investment advice.\n\nhttps://trialsonar.netlify.a
 pp/radar.html?nct=NCT05911295\nhttps://clinicaltrials.gov/study/NCT0591129
 5
URL:https://trialsonar.netlify.app/radar.html?nct=NCT05911295
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06551324-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:MEVPRO-1 readout (P3) · Pfizer $PFE
DESCRIPTION:A Study to Learn About the Investigational Medicine Called PF-0
 6821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With
  Abiraterone Acetate for Prostate Cancer (…\n\nPrimary completion date: 
 2027-02-28 (estimated)\nOriginally planned: 2025-12-17 (+14.4 months)\nPha
 se 3 · Oncology · Metastatic Castrate Resistant Prostate Cancer (mCRPC)\
 nEnrollment: 609 · Sites: 224\n\nPrimary completion = last participant's 
 primary-endpoint data collected\; topline results usually follow weeks to 
 months later. Sponsor-reported\, often an estimate. Not investment advice.
 \n\nhttps://trialsonar.netlify.app/radar.html?nct=NCT06551324\nhttps://cli
 nicaltrials.gov/study/NCT06551324
URL:https://trialsonar.netlify.app/radar.html?nct=NCT06551324
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06524414-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270304
DTEND;VALUE=DATE:20270305
SUMMARY:PG4 readout (P2) · Pfizer $PFE
DESCRIPTION:A Study to Learn About How a New Pneumococcal Vaccine Works in 
 Infants\n\nPrimary completion date: 2027-03-04 (estimated)\nOriginally pla
 nned: 2026-07-14 (+7.7 months)\nPhase 2 · Infectious · Pneumococcal Dise
 ase\nEnrollment: 605 · Sites: 67\n\nPrimary completion = last participant
 's primary-endpoint data collected\; topline results usually follow weeks 
 to months later. Sponsor-reported\, often an estimate. Not investment advi
 ce.\n\nhttps://trialsonar.netlify.app/radar.html?nct=NCT06524414\nhttps://
 clinicaltrials.gov/study/NCT06524414
URL:https://trialsonar.netlify.app/radar.html?nct=NCT06524414
CATEGORIES:Infectious,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06977581-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270308
DTEND;VALUE=DATE:20270309
SUMMARY:PF-07275315 readout (P2) · Pfizer $PFE
DESCRIPTION:A Study to Learn About the Study Medicine Called PF-07275315 in
  People With Moderate-To-Severe Asthma\n\nPrimary completion date: 2027-03
 -08 (estimated)\nPhase 2 · Respiratory · Asthma\nEnrollment: 252 · Site
 s: 137\n\nPrimary completion = last participant's primary-endpoint data co
 llected\; topline results usually follow weeks to months later. Sponsor-re
 ported\, often an estimate. Not investment advice.\n\nhttps://trialsonar.n
 etlify.app/radar.html?nct=NCT06977581\nhttps://clinicaltrials.gov/study/NC
 T06977581
URL:https://trialsonar.netlify.app/radar.html?nct=NCT06977581
CATEGORIES:Respiratory,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04624230-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270317
DTEND;VALUE=DATE:20270318
SUMMARY:tofacitinib readout (P3) · Pfizer $PFE
DESCRIPTION:Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years O
 ld Suffering From Moderate to Severe Ulcerative Colitis\n\nPrimary complet
 ion date: 2027-03-17 (estimated)\nOriginally planned: 2025-12-16 (+15.0 mo
 nths)\nPhase 3 · GI·Renal·Heme · Ulcerative Colitis\nEnrollment: 118 
 · Sites: 69\n\nPrimary completion = last participant's primary-endpoint d
 ata collected\; topline results usually follow weeks to months later. Spon
 sor-reported\, often an estimate. Not investment advice.\n\nhttps://trials
 onar.netlify.app/radar.html?nct=NCT04624230\nhttps://clinicaltrials.gov/st
 udy/NCT04624230
URL:https://trialsonar.netlify.app/radar.html?nct=NCT04624230
CATEGORIES:GI·Renal·Heme,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05639647-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:ATM-AVI readout (P2) · Pfizer $PFE
DESCRIPTION:Study of 2 Medicines (Aztreonam and Avibactam) Compared to Best
  Available Therapy for Serious Gram-negative Infections\n\nPrimary complet
 ion date: 2027-03-31 (estimated)\nOriginally planned: 2025-12-24 (+15.2 mo
 nths)\nPhase 2 · Infectious · Gram-negative Bacterial Infections\nEnroll
 ment: 48 · Sites: 22\n\nPrimary completion = last participant's primary-e
 ndpoint data collected\; topline results usually follow weeks to months la
 ter. Sponsor-reported\, often an estimate. Not investment advice.\n\nhttps
 ://trialsonar.netlify.app/radar.html?nct=NCT05639647\nhttps://clinicaltria
 ls.gov/study/NCT05639647
URL:https://trialsonar.netlify.app/radar.html?nct=NCT05639647
CATEGORIES:Infectious,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06163326-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Tranquillo LTE readout (P3) · Pfizer $PFE
DESCRIPTION:A 52-Week Study to Learn About the Safety and Effects of Ritlec
 itinib in Participants With Nonsegmental Vitiligo\n\nPrimary completion da
 te: 2027-03-31 (estimated)\nOriginally planned: 2026-08-07 (+7.8 months)\n
 Phase 3 · Immuno · Vitiligo\nEnrollment: 394 · Sites: 73\n\nPrimary com
 pletion = last participant's primary-endpoint data collected\; topline res
 ults usually follow weeks to months later. Sponsor-reported\, often an est
 imate. Not investment advice.\n\nhttps://trialsonar.netlify.app/radar.html
 ?nct=NCT06163326\nhttps://clinicaltrials.gov/study/NCT06163326
URL:https://trialsonar.netlify.app/radar.html?nct=NCT06163326
CATEGORIES:Immuno,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06462235-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270425
DTEND;VALUE=DATE:20270426
SUMMARY:CHERISH readout (P2) · Pfizer $PFE
DESCRIPTION:A Study to Learn About the Study Medicine Aztreonam-Avibactam (
 ATM-AVI) in Infants and Newborns Admitted in Hospitals With Bacterial Infe
 ction (CHERISH)\n\nPrimary completion date: 2027-04-25 (estimated)\nOrigin
 ally planned: 2027-09-27 (-5.1 months)\nPhase 2 · Infectious · Gram-nega
 tive Bacterial Infection\nEnrollment: 48 · Sites: 32\n\nPrimary completio
 n = last participant's primary-endpoint data collected\; topline results u
 sually follow weeks to months later. Sponsor-reported\, often an estimate.
  Not investment advice.\n\nhttps://trialsonar.netlify.app/radar.html?nct=N
 CT06462235\nhttps://clinicaltrials.gov/study/NCT06462235
URL:https://trialsonar.netlify.app/radar.html?nct=NCT06462235
CATEGORIES:Infectious,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07794748-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270426
DTEND;VALUE=DATE:20270427
SUMMARY:PG4 Multivalent Vaccine readout (P3) · Pfizer $PFE
DESCRIPTION:A Study to Assess the Safety\, Tolerability\, and Immunogenicit
 y of 3 Lots of a Multivalent Pneumococcal Conjugate Vaccine Administered t
 o Adults\n\nPrimary completion date: 2027-04-26 (estimated)\nOriginally pl
 anned: 2027-06-07 (-1.4 months)\nPhase 3 · Infectious · Pneumococcal Dis
 ease\nEnrollment: 4701 · Sites: 37\n\nPrimary completion = last participa
 nt's primary-endpoint data collected\; topline results usually follow week
 s to months later. Sponsor-reported\, often an estimate. Not investment ad
 vice.\n\nhttps://trialsonar.netlify.app/radar.html?nct=NCT07794748\nhttps:
 //clinicaltrials.gov/study/NCT07794748
URL:https://trialsonar.netlify.app/radar.html?nct=NCT07794748
CATEGORIES:Infectious,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06807268-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270502
DTEND;VALUE=DATE:20270503
SUMMARY:Abrocitinib readout (P3) · Pfizer $PFE
DESCRIPTION:A Study of the Medicine Called Abrocitinib in Children 6 to Les
 s Than 12 Years of Age With Moderate-to-Severe Eczema\n\nPrimary completio
 n date: 2027-05-02 (estimated)\nOriginally planned: 2027-03-24 (+1.3 month
 s)\nPhase 3 · Immuno · Eczema\nEnrollment: 151 · Sites: 47\n\nPrimary c
 ompletion = last participant's primary-endpoint data collected\; topline r
 esults usually follow weeks to months later. Sponsor-reported\, often an e
 stimate. Not investment advice.\n\nhttps://trialsonar.netlify.app/radar.ht
 ml?nct=NCT06807268\nhttps://clinicaltrials.gov/study/NCT06807268
URL:https://trialsonar.netlify.app/radar.html?nct=NCT06807268
CATEGORIES:Immuno,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07819097-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270516
DTEND;VALUE=DATE:20270517
SUMMARY:RSVpreF readout (P3) · Pfizer $PFE
DESCRIPTION:A Study to Learn About the Safety and Immune Responses of RSVpr
 eF in Older Adults\n\nPrimary completion date: 2027-05-16 (estimated)\nPha
 se 3 · Other · Adult\, Healthy Participants\nEnrollment: 600 · Sites: 1
 5\n\nPrimary completion = last participant's primary-endpoint data collect
 ed\; topline results usually follow weeks to months later. Sponsor-reporte
 d\, often an estimate. Not investment advice.\n\nhttps://trialsonar.netlif
 y.app/radar.html?nct=NCT07819097\nhttps://clinicaltrials.gov/study/NCT0781
 9097
URL:https://trialsonar.netlify.app/radar.html?nct=NCT07819097
CATEGORIES:Other,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07431853-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270622
DTEND;VALUE=DATE:20270623
SUMMARY:Vaccine Candidate #1 readout (P2) · Pfizer $PFE
DESCRIPTION:A Study to Learn About mRNA Vaccines Against Influenza in Adult
 s\n\nPrimary completion date: 2027-06-22 (estimated)\nOriginally planned: 
 2026-10-22 (+8.0 months)\nPhase 2 · Infectious · Healthy Adults\nEnrollm
 ent: 770 · Sites: 15\n\nPrimary completion = last participant's primary-e
 ndpoint data collected\; topline results usually follow weeks to months la
 ter. Sponsor-reported\, often an estimate. Not investment advice.\n\nhttps
 ://trialsonar.netlify.app/radar.html?nct=NCT07431853\nhttps://clinicaltria
 ls.gov/study/NCT07431853
URL:https://trialsonar.netlify.app/radar.html?nct=NCT07431853
CATEGORIES:Infectious,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07062965-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270722
DTEND;VALUE=DATE:20270723
SUMMARY:PF-07248144 readout (P3) · Pfizer $PFE
DESCRIPTION:A Study to Learn About the Study Medicine Called PF-07248144 in
  Combination With Fulvestrant in People With HR-positive\, HER2-negative A
 dvanced or Metastatic Breast Cancer Who Pro…\n\nPrimary completion date:
  2027-07-22 (estimated)\nOriginally planned: 2027-11-02 (-3.4 months)\nPha
 se 3 · Oncology · Breast Cancer\nEnrollment: 400 · Sites: 433\n\nPrimar
 y completion = last participant's primary-endpoint data collected\; toplin
 e results usually follow weeks to months later. Sponsor-reported\, often a
 n estimate. Not investment advice.\n\nhttps://trialsonar.netlify.app/radar
 .html?nct=NCT07062965\nhttps://clinicaltrials.gov/study/NCT07062965
URL:https://trialsonar.netlify.app/radar.html?nct=NCT07062965
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06072183-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:Tranquillo 2 readout (P3) · Pfizer $PFE
DESCRIPTION:A 104-Week Study of Ritlecitinib Oral Capsules in Adults With N
 onsegmental Vitiligo (Active and Stable) Tranquillo 2\n\nPrimary completio
 n date: 2027-07-30 (estimated)\nPhase 3 · Immuno · Stable Nonsegmental V
 itiligo\, Active Nonsegmental Vitiligo\nEnrollment: 1571 · Sites: 229\n\n
 Primary completion = last participant's primary-endpoint data collected\; 
 topline results usually follow weeks to months later. Sponsor-reported\, o
 ften an estimate. Not investment advice.\n\nhttps://trialsonar.netlify.app
 /radar.html?nct=NCT06072183\nhttps://clinicaltrials.gov/study/NCT06072183
URL:https://trialsonar.netlify.app/radar.html?nct=NCT06072183
CATEGORIES:Immuno,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05317416-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270804
DTEND;VALUE=DATE:20270805
SUMMARY:MagnetisMM-7 readout (P3) · Pfizer $PFE
DESCRIPTION:Study With Elranatamab Versus Lenalidomide in Patients With New
 ly Diagnosed Multiple Myeloma After Transplant\n\nPrimary completion date:
  2027-08-04 (estimated)\nOriginally planned: 2027-06-23 (+1.4 months)\nPha
 se 3 · Oncology · Multiple Myeloma\nEnrollment: 854 · Sites: 209\n\nPri
 mary completion = last participant's primary-endpoint data collected\; top
 line results usually follow weeks to months later. Sponsor-reported\, ofte
 n an estimate. Not investment advice.\n\nhttps://trialsonar.netlify.app/ra
 dar.html?nct=NCT05317416\nhttps://clinicaltrials.gov/study/NCT05317416
URL:https://trialsonar.netlify.app/radar.html?nct=NCT05317416
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07575932-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270804
DTEND;VALUE=DATE:20270805
SUMMARY:SOLIS-1 readout (P2) · Pfizer $PFE
DESCRIPTION:A Study of PF-08653945 and PF-08653944 in Adults With Overweigh
 t or Obesity\n\nPrimary completion date: 2027-08-04 (estimated)\nPhase 2 
 · Cardio-Met · Overweight\, Obesity\, Overweight and/or Obesity\nEnrollm
 ent: 940 · Sites: 63\n\nPrimary completion = last participant's primary-e
 ndpoint data collected\; topline results usually follow weeks to months la
 ter. Sponsor-reported\, often an estimate. Not investment advice.\n\nhttps
 ://trialsonar.netlify.app/radar.html?nct=NCT07575932\nhttps://clinicaltria
 ls.gov/study/NCT07575932
URL:https://trialsonar.netlify.app/radar.html?nct=NCT07575932
CATEGORIES:Cardio-Met,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07311850-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270921
DTEND;VALUE=DATE:20270922
SUMMARY:VESPER-4 readout (P3) · Pfizer $PFE
DESCRIPTION:Efficacy and Safety of MET097 Once-Weekly in People With Overwe
 ight or Obesity\n\nPrimary completion date: 2027-09-21 (estimated)\nPhase 
 3 · Cardio-Met · Obesity and Overweight\nEnrollment: 3578 · Sites: 161\
 n\nPrimary completion = last participant's primary-endpoint data collected
 \; topline results usually follow weeks to months later. Sponsor-reported\
 , often an estimate. Not investment advice.\n\nhttps://trialsonar.netlify.
 app/radar.html?nct=NCT07311850\nhttps://clinicaltrials.gov/study/NCT073118
 50
URL:https://trialsonar.netlify.app/radar.html?nct=NCT07311850
CATEGORIES:Cardio-Met,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07013474-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270928
DTEND;VALUE=DATE:20270929
SUMMARY:ibuzatrelvir readout (P3) · Pfizer $PFE
DESCRIPTION:A Study to Learn About the Study Medicine Ibuzatrelvir in Adult
 s With COVID-19 Who Are Severely Immunocompromised\n\nPrimary completion d
 ate: 2027-09-28 (estimated)\nOriginally planned: 2026-12-06 (+9.7 months)\
 nPhase 3 · Infectious · COVID-19 Infection\nEnrollment: 300 · Sites: 15
 9\n\nPrimary completion = last participant's primary-endpoint data collect
 ed\; topline results usually follow weeks to months later. Sponsor-reporte
 d\, often an estimate. Not investment advice.\n\nhttps://trialsonar.netlif
 y.app/radar.html?nct=NCT07013474\nhttps://clinicaltrials.gov/study/NCT0701
 3474
URL:https://trialsonar.netlify.app/radar.html?nct=NCT07013474
CATEGORIES:Infectious,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06629779-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:PF-06821497 readout (P3) · Pfizer $PFE
DESCRIPTION:A Study to Learn How PF-06821497 (Mevrometostat) Works in Men W
 ith Metastatic Castration-resistant Prostate Cancer.\n\nPrimary completion
  date: 2027-09-30 (estimated)\nOriginally planned: 2026-07-24 (+14.2 month
 s)\nPhase 3 · Oncology · Metastatic Castration-Resistant Prostate Cancer
 \nEnrollment: 900 · Sites: 231\n\nPrimary completion = last participant's
  primary-endpoint data collected\; topline results usually follow weeks to
  months later. Sponsor-reported\, often an estimate. Not investment advice
 .\n\nhttps://trialsonar.netlify.app/radar.html?nct=NCT06629779\nhttps://cl
 inicaltrials.gov/study/NCT06629779
URL:https://trialsonar.netlify.app/radar.html?nct=NCT06629779
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06679140-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:ibuzatrelvir readout (P3) · Pfizer $PFE
DESCRIPTION:A Study to Learn About a Study Medicine Called Ibuzatrelvir in 
 Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But A
 re at Risk For Severe Disease\n\nPrimary completion date: 2027-10-01 (esti
 mated)\nOriginally planned: 2026-11-24 (+10.2 months)\nPhase 3 · Infectio
 us · COVID-19 SARS-CoV-2 Infection\nEnrollment: 2330 · Sites: 256\n\nPri
 mary completion = last participant's primary-endpoint data collected\; top
 line results usually follow weeks to months later. Sponsor-reported\, ofte
 n an estimate. Not investment advice.\n\nhttps://trialsonar.netlify.app/ra
 dar.html?nct=NCT06679140\nhttps://clinicaltrials.gov/study/NCT06679140
URL:https://trialsonar.netlify.app/radar.html?nct=NCT06679140
CATEGORIES:Infectious,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07400653-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20271012
DTEND;VALUE=DATE:20271013
SUMMARY:PF-08653944 readout (P3) · Pfizer $PFE
DESCRIPTION:A Study to Learn About the Study Medicine (PF-08653944) in Peop
 le With Obesity or Overweight and Type 2 Diabetes (T2D)\n\nPrimary complet
 ion date: 2027-10-12 (estimated)\nPhase 3 · Cardio-Met · Obesity\, Overw
 eight and/or Obesity\, Overweight\nEnrollment: 1078 · Sites: 180\n\nPrima
 ry completion = last participant's primary-endpoint data collected\; topli
 ne results usually follow weeks to months later. Sponsor-reported\, often 
 an estimate. Not investment advice.\n\nhttps://trialsonar.netlify.app/rada
 r.html?nct=NCT07400653\nhttps://clinicaltrials.gov/study/NCT07400653
URL:https://trialsonar.netlify.app/radar.html?nct=NCT07400653
CATEGORIES:Cardio-Met,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
